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donor chimaerism. Megakaryocytes were
abundant and appeared normal. Analysis
of lymphocyte subsets revealed rapid
recovery of CD19+ B cells (131/1-'1, inc!.
CD5+CD19+ cells) in comparison with the
previous examination a month ago (9/1-'1)
and substantial number of CD3+CD4+ Th
cells (> 100/1-'1). Steroid-treatment was
ineffective and she received high-dose
(HD) IVIG (2g/kg over 4 days) with
sustained curative effect. She remains
now in CR of both MDS and ITP with
100% donor chimaerism (XY-FISH).
Patient UPN 142. 10-month-old boy with
Omenn Syndrome underwent allogeneic
haploidentical T-cell depleted (TCD)
PBSCT from HLA-mismatched mother
in October 1999. He was conditioned with
Bu 20mg/kg, TT 10mg/kg, Flu 200mg/m2
and OKT-3. GvHD prophylaxis consisted
of TCD (CliniMACS®), CsA, MP and MMF.
Hematological recovery was prompt: ANC
> 0.5 GIl on day +9, platelets > 50 GIl
on day +30. Neither GvHD nor other
serious complications were observed until
May 2000 (217 days after transplantation),
when he developed ITP. with a platelet
count of 31 GIL Chimaerism analysis
confirmed 100% donor engraftment.
Immune studies revealed rapid recovery
of CD19+ B cells (324/1-'1, incl.
CD5+CD19+ cells) in comparison with
the previous examination two months ago
(57/1-'1) and peripheral expansion
of CD3+CD4+ cells (> 400/1-'1) incl.
CD4+CD69+ cells. Different modalities
for treatment of ITP were tried with
transient success. Prednisone (4mg/kg)
together with IVIG (OAg/kg) resulted in ITP
resolution lasting 2 months. Platelet count
dropped again to 51 G/l in August 2000
and HD IVIG (2g/kg) was administered
with good yet transient effect. Four more
HD IVIG courses every month were
required to attain final ITP resolution
in January 2001 - 14 months post
transplant. The child remains now alive
and well with platelet count above 200 GIL
Conclusions. Rapid B cell recovery
correlates with the occurrence of late
onset steroid-resistant ITP in recipients
of alternative transplants. Th (CD3+CD4+)
cell recovery might also trigger
autoimmunity by IL-2 mediated non-
specific immune activation. The treatment
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of choice remains HD IVIG. Anti-D
immunoglobulin might be used in Rh-
positive patients. A novel highly effective
option might be therapy with chimeric
monoclonal anti-CD 20 antibody (rituximab
- Mabthera®).
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Wilms' tumour (WT) is the most common
primary genitourinary tumour of childhood
with the annual incidence of approximately
8 per million children younger than
15 years of age. Genetic plays an impor-
tant role in this cancer. WT1 located
on chromosome 11 p13, WT2 on 11 p15,
loci at 1p, 7p, 16q, 17p (the p53 tumor
suppressor gene), and 19q (the putative
familial WT gene FWT2) are believed
to harbor genes involved in the biology
of WT. The majority of these children are
surviving into adult life and due to the
combination of genetic susceptibility,
irradiation and antineoplastic treatment,
are at increased risk for second malignant
neoplasms (SMNs). We report the case
of a young man with a parotid carcinoma
occurring thirteen years after diagnosis
of WT. The patient was initially treated
according to the SlOP 6 Nephroblastoma
protocol, comprising a 4-week two-drug
(Actinomycin 0, Vincristine) presurgical
treatment, nephrectomy and 22-week
treatment with biweekly Actinomycin 0
and Vincristine. No radiation therapy was
given. Nine months after the end of the-
rapy he experienced an isolated hepatic
relapse, treated with Peptichemio
(450 mg/m2), two courses of Cisplatin
(40 mg/m2/day for 5 days) and Etoposide
S17
(100 mg/m2/day for 5 days) and two
cycles of the combination Ifosfamide
(2 gr/m2/day for 5 days), Doxorubicin
(40 mg/m2/day for 2 days), Vincristine
(1.5 mg/m2). Resection of a complete
necrotic lesion at the fourth hepatic
segment was subsequently performed.
Treatment was completed with high dose
association of Melphalan (200 mg/M2) and
Vincristine (4 mg/M2) followed by auto-
logous bone marrow transplantation
(BMT). After 13 years since WT diagnosis
and 11 years after BMT the patient pre-
sented a right non tender, homogeneous
and mobile parotideal mass. After the total
parotidectomy the diagnosis was con-
sistent with a low-grade mucoepidermoidal
carcinoma. In the National WT Study
Group review regarding 43 SMNs out
of 5278 patients enrolled between 1969
and 1991 the relevant risk factor for de-
veloping a SMN were radiation therapy
(RT), the association of Doxo-rubicin and
RT and utilization of chemo-therapy
for the treatment of the relapse. All these
risk factors were present in the only repor-
ted case of parotideal carcinoma in these
series. In the SlOP survey RT was related
to secondary bone cancer and the use
of epipodophyllotoxin with leukemia occu-
rrence. On these basis in our patient
a clear pathogenetic mechanism is lac-
king, then we can also attribute the secon-
dary parotid carcinoma simply to the chan-
ce. Physician needto be aware that even
unusual SMNs, can develop also in sub-
jects that for their primary malignancy
and related treatment are at low risk.
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AN ANALYSIS OF THE DOSES
CALCULATED AND MEASURED
IN-VIVO DURING TOTAL BODY
IRRADIATION
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Medical Physics Department, Great
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Purpose: The aim of this work was
to estimate the error in dose calculations,
to check the agreement between the mea-
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sured and calculated doses and to analyse
dose discrepancies in the group of thirty
patients undergoing total body irradiation.
Method: A group of thirty consecutive
patients, children aged from 5 to 12 years,
was taken for dose comparison. A combi-
nation of lateral and anterior - posterior
fields with electron boost was used in eight
fractions and on four consecutive days.
Cobalt unit was used as a source of ra-
diation. Lung shields were used· at two
anterior-posterior fields. Compensators
were attached at the neck, head and legs.
Doses were preliminarily calculated and
then measured in-vivo by thermo-
luminescent (TLD) and semiconductor
(SEM) detectors attached to the body in ten
representative transverse cross-sections.
Calculations and measurements were
carried out for the beam at the body entry
and exit. The error in dose calculations was
estimated for each dosimetrical point.
A total dose of 12,6 Gy was prescribed
in the body midline on the central beam axis
(CAX). A dose of 8.2 Gy was delivered from
six lateral fields and a dose of 4,4 Gy from
two AP/PA fields. In the lungs dose was
below 10 Gy. Lateral fields were set at
a source to skin distance (SSD) of 305 cm
with the dose rate to midline of 5,9 cGy/min
and AP/PA fields were set at 210 cm with
11,5 cGy/min, respectively. A fractional
dose specified on CAX and midline was
2.5 Gy during all anterior-posterior fields
(from each side), 1.5 Gy (0.75 Gy from each
side) during four lateral fields, and 1.1 Gy
(0.55 Gy from each side) during two lateral
fields.
Results: The error in the preliminary dose
calculations was determined by a total
differential method, taking into account
of the accuracy of determining the following
parameters: SSD, body thickness and con-
tour, the thickness of compensators, lung
shields, filter shape, lung dimensions and
body density, where applicable. Calcu-
lations were done separately for each
cross-section and for the beam entry
and exit. The values of this error were
rounded up to 3% for CAX, from 5% to 10%
for head, neck, shoulders, abdomen,
elbows, wrist, knee and feet and increased
to 15% for lung at AP/PA fields. Per cent
deviations for hole group of patients
for lateral and AP/PA fields (on entry
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